Cellivery Obtains Patent Rights in Europe for Candidate Substances Treating Severe Obesity and Diabetes

[Asia Economy Reporter Minji Lee] Cellivery announced on the 17th that it has obtained a patent for a candidate substance for the treatment of severe obesity and diabetes with leptin resistance.

The patent registration country is the European Union. The company explained, "We can negotiate from a favorable position during technology transfer discussions with global pharmaceutical companies."